ADCK1: A Potential Drug Target and Biomarker for Prostate and Lung Cancer

Target Name: ADCK1

NCBI ID: G57143

ADCK1

ADCK1: A Potential Drug Target and Biomarker for Prostate and Lung Cancer

Prostate and lung cancer are two of the leading causes of cancer-related deaths worldwide, with increasing incidence rates in both men and women. The development of new therapeutic approaches to target these cancers is crucial for improving treatment outcomes. One promising candidate for cancer therapy is the AarF domain-containing protein kinase 1 (ADCK1), which has been identified as a potential drug target and biomarker for prostate and lung cancer.

ADCK1: Structure and Function

ADCK1 is a protein that belongs to the serine/threonine protein kinase family, which is known for their role in cell signaling pathways. ADCK1 is primarily localized to the nuclear envelope and is involved in regulating various cellular processes, including cell adhesion, migration, and survival.

The AarF domain is a unique protein kinase domain that is characterized by a specific arrangement of amino acids. This domain is found in several protein kinases, including PDK4 (Pten), TPK5 (Tpk), and casein kinase 3 (Csk). The AarF domain is named after its first identified member, AarF2, which is a protein that is involved in cell signaling pathways.

ADCK1 is a 21-kDa protein that is expressed in various tissues, including brain, heart, liver, and cancer cells. It is highly conserved, with a calculated pI of 6.97 and a predicted localization in the cytoplasm. ADCK1 has been shown to play a role in regulating cell adhesion and migration, as well as cell survival and angiogenesis.

ADCK1 as a Drug Target

ADCK1 is a potential drug target for prostate and lung cancer because of its involvement in various cellular processes that are associated with the development of these cancers. One of the main mechanisms by which ADCK1 contributes to cancer progression is its role in cell adhesion and migration.

Studies have shown that cancer cells often have increased adhesion and migration capabilities compared to normal cells. This is because cancer cells have altered cell adhesion molecules (such as E-cadherin) and increased levels of mobile adhesion domain (MAD) proteins (such as N-cadherin). ADCK1 is known to be involved in the regulation of these processes, and it has been shown to promote the assembly and stability of MAD proteins.

In addition to its role in cell adhesion and migration, ADCK1 has also been shown to contribute to cancer cell survival. Studies have shown that cancer cells are more resistant to apoptosis (programmed cell death) compared to normal cells, and this is thought to be due to the ability of cancer cells to evade the negative effects of ADCK1.

ADCK1 as a Biomarker

ADCK1 has also been identified as a potential biomarker for prostate and lung cancer. The identification of cancer biomarkers is important for the development of new diagnostic tests and for the evaluation of cancer treatment.

Studies have shown that ADCK1 is expressed in various tissues and cell types, including cancer cells, metastatic cells, and normal tissues. This makes it a potential target for cancer diagnostic tests. In addition, the ability of ADCK1 to promote the assembly and stability of MAD proteins has been shown to be associated with cancer cell survival, which could be used as a biomarker for cancer progression.

Conclusion

ADCK1 is a protein that has been identified as a potential drug target and biomarker for prostate and lung cancer. Its role in cell adhesion and migration, as well as its involvement in cancer cell survival, make it a promising candidate for cancer therapy. Further research is needed to

Protein Name: AarF Domain Containing Kinase 1

Functions: Appears to be essential for maintaining mitochondrial cristae formation and mitochondrial function by acting via YME1L1 in a kinase-independent manner to regulate essential mitochondrial structural proteins OPA1 and IMMT (PubMed:31125351). The action of this enzyme is not yet clear (Probable). It is not known if it has protein kinase activity and what type of substrate it would phosphorylate (Ser, Thr or Tyr) (Probable)

The "ADCK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADCK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets